Astria Therapeutics (NASDAQ:ATXS) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS) in a research note issued to investors on Friday,Benzinga reports. They currently have a $16.00 price target on the biotechnology company’s stock.

ATXS has been the topic of several other research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $47.00 price target on shares of Astria Therapeutics in a report on Wednesday, May 14th. Wedbush reiterated an “outperform” rating and issued a $28.00 price target (up previously from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $30.00.

Astria Therapeutics Stock Up 2.1%

Shares of NASDAQ ATXS opened at $5.72 on Friday. Astria Therapeutics has a 52 week low of $3.56 and a 52 week high of $12.92. The firm’s fifty day moving average is $4.61 and its 200 day moving average is $6.59. The company has a market cap of $322.80 million, a price-to-earnings ratio of -2.74 and a beta of 0.39.

Astria Therapeutics (NASDAQ:ATXS) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.10). Equities research analysts anticipate that Astria Therapeutics will post -1.65 earnings per share for the current year.

Institutional Trading of Astria Therapeutics

A number of hedge funds have recently modified their holdings of ATXS. KLP Kapitalforvaltning AS bought a new stake in shares of Astria Therapeutics during the 4th quarter valued at $41,000. GAMMA Investing LLC boosted its holdings in shares of Astria Therapeutics by 1,127.4% during the 1st quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 7,971 shares in the last quarter. Brooklyn Investment Group boosted its holdings in shares of Astria Therapeutics by 1,079.6% during the 1st quarter. Brooklyn Investment Group now owns 8,694 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 7,957 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Astria Therapeutics by 109.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 2,766 shares in the last quarter. Finally, BNP Paribas Financial Markets bought a new stake in shares of Astria Therapeutics during the 4th quarter valued at $50,000. Institutional investors own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.